Life-extending capacity of new cancer drugs varies widely
Researchers looked at the 62 cancer drugs approved in the U.S. and Europe between 2003 and 2013 and found they extended survival by an average of about 3.5 months.
Tue Jan 03 2017
Pfizer boosts cancer drug roster with $14 billion Medivation deal
Pfizer Inc said it agreed to buy US cancer drug company Medivation Inc for $14 billion in cash.
Tue Aug 23 2016
Roche says new drug shows benefits in lung, bladder cancer tests
Roche's new immune-system boosting cancer drug has given positive results in tests on patients suffering from some lung and bladder cancers.
Sun Sep 27 2015